Last reviewed · How we verify
Falciparum Malaria Protein 11 with AS02A adjuvant
Falciparum Malaria Protein 11 with AS02A adjuvant is a Biologic drug developed by U.S. Army Medical Research and Development Command. It is currently in Phase 1 development.
At a glance
| Generic name | Falciparum Malaria Protein 11 with AS02A adjuvant |
|---|---|
| Sponsor | U.S. Army Medical Research and Development Command |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Falciparum Malaria Protein 11 with AS02A adjuvant CI brief — competitive landscape report
- Falciparum Malaria Protein 11 with AS02A adjuvant updates RSS · CI watch RSS
- U.S. Army Medical Research and Development Command portfolio CI
Frequently asked questions about Falciparum Malaria Protein 11 with AS02A adjuvant
What is Falciparum Malaria Protein 11 with AS02A adjuvant?
Falciparum Malaria Protein 11 with AS02A adjuvant is a Biologic drug developed by U.S. Army Medical Research and Development Command.
Who makes Falciparum Malaria Protein 11 with AS02A adjuvant?
Falciparum Malaria Protein 11 with AS02A adjuvant is developed by U.S. Army Medical Research and Development Command (see full U.S. Army Medical Research and Development Command pipeline at /company/u-s-army-medical-research-and-development-command).
What development phase is Falciparum Malaria Protein 11 with AS02A adjuvant in?
Falciparum Malaria Protein 11 with AS02A adjuvant is in Phase 1.